Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sijing Li

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|March 2, 2024
Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter studyXingling He, Donghua Liu, Shihao Ni, et al.
Cell Death and Differentiation|November 16, 2024
ACBP/DBI neutralization for the experimental treatment of fatty liver diseaseOmar Motiño, Flavia Lambertucci, Adrien Joseph, et al.
Cell Death and Differentiation|March 14, 2025
Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritisUxía Nogueira-Recalde, Flavia Lambertucci, Léa Montégut, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2022
ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosisOmar Motiño, Flavia Lambertucci, Gerasimos Anagnostopoulos, et al.
Cell Death & Disease|April 6, 2024
Inhibition of acyl-CoA binding protein (ACBP) by means of a GABA<sub>A</sub>Rγ2-derived peptideGerasimos Anagnostopoulos, Ester Saavedra, Flavia Lambertucci, et al.
Cell Death and Differentiation|June 3, 2026
Cell death-induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulationYan Rong, Flavia Lambertucci, Yaning Yang, et al.
Cell Death & Disease|April 19, 2022
An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABA<sub>A</sub> receptorGerasimos Anagnostopoulos, Omar Motiño, Sijing Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Acyl-CoA-binding protein as a driver of pathological agingLéa Montégut, Flavia Lambertucci, Lucas Moledo-Nodar, et al.
Signal Transduction and Targeted Therapy|April 2, 2026
Acyl-CoA-binding protein (ACBP): a poor-prognosis biomarker in sepsis and a target for disease mitigationFlavia Lambertucci, Omar Motiño, Uxía Nogueira-Recalde, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|March 2, 2024
Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter studyXingling He, Donghua Liu, Shihao Ni, et al.
Cell Death and Differentiation|November 16, 2024
ACBP/DBI neutralization for the experimental treatment of fatty liver diseaseOmar Motiño, Flavia Lambertucci, Adrien Joseph, et al.
Cell Death and Differentiation|March 14, 2025
Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritisUxía Nogueira-Recalde, Flavia Lambertucci, Léa Montégut, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2022
ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosisOmar Motiño, Flavia Lambertucci, Gerasimos Anagnostopoulos, et al.
Cell Death & Disease|April 6, 2024
Inhibition of acyl-CoA binding protein (ACBP) by means of a GABA<sub>A</sub>Rγ2-derived peptideGerasimos Anagnostopoulos, Ester Saavedra, Flavia Lambertucci, et al.
Cell Death and Differentiation|June 3, 2026
Cell death-induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulationYan Rong, Flavia Lambertucci, Yaning Yang, et al.
Cell Death & Disease|April 19, 2022
An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABA<sub>A</sub> receptorGerasimos Anagnostopoulos, Omar Motiño, Sijing Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Acyl-CoA-binding protein as a driver of pathological agingLéa Montégut, Flavia Lambertucci, Lucas Moledo-Nodar, et al.
Signal Transduction and Targeted Therapy|April 2, 2026
Acyl-CoA-binding protein (ACBP): a poor-prognosis biomarker in sepsis and a target for disease mitigationFlavia Lambertucci, Omar Motiño, Uxía Nogueira-Recalde, et al.
Pageof 11